Evidence map›Paper›PMID 19041059›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2008

Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation.

Jan Storek, Zhao Zhao, Yiping Liu, Richard Nash, Peter McSweeney, David G Maloney

Open access · bronzeAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jan StorekFred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA. jstorek@ucalgary.ca
Zhao Zhao
Yiping Liu
Richard Nash
Peter McSweeney
David G Maloney
University of Washington · USFred Hutch Cancer Center · USUniversity of Calgary · CA

Funding

T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTINGR01AI046108 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STOREK, JAN · 1999 to 2003
$1.1M
NIAID NIH HHS AI46108NIAID NIH HHS R01 AI046108
6 · The paper itself

Abstract

T cell diversity posttransplantation is thought to be severely restricted, based on T cell receptor beta-chain immunophenotyping or spectratyping. Using beta-chain sequencing, we studied CD4 T cell diversity in 2 adult patients undergoing "lymphoablative" conditioning with cyclophosphamide (Cy), total body irradiation (TBI), and antithymocyte globulin (ATG) and autologous transplantation of hematopoietic cells depleted of T cells by enrichment for CD34 cells. The indication for the transplantation was systemic sclerosis (SSc) or multiple sclerosis (MS). Pretransplantation, the estimated number of distinct beta chains (the minimum number of CD4 T cell clones) in the 2 patients was 600,000 to 700,000, similar to the number in a healthy control. This number was 200,000 to 500,000 at 1 month posttransplantation and 400,000 to 1,600,000 at 12 months posttransplantation. In conclusion, the number of T cells early after lymphoablative conditioning and autologous CD34 cell transplantation may be more diverse than previously appreciated, possibly because many T cell clones survive the conditioning or are reinfused with the graft. Thus, the therapy may not be completely T cell lymphoablative.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningAdultAntigens, CD34Antilymphocyte SerumCD4-Positive T-LymphocytesCyclophosphamideFemaleHumansImmunosuppressive AgentsLymphocyte DepletionMaleMiddle AgedMultiple SclerosisMyeloablative AgonistsReceptors, Antigen, T-Cell, alpha-betaAntigens, CD34Antilymphocyte SerumCyclophosphamideImmunosuppressive AgentsMyeloablative AgonistsReceptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID19041059
PMCPMC2704065
OpenAlexW2089965069

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.